Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London

Core Insights - Helix BioPharma Corp. presented new data on its CEACAM6-directed antibody-drug conjugate (ADC) program at the 16th Annual World ADC London conference, highlighting its commitment to developing innovative cancer therapies [1][2] Group 1: Presentation Highlights - The presentation titled "Next-Generation ADCs: Unlocking the Potential of CEACAM6-Directed Targeted Therapies" was delivered by Dr. Jonathan Davis, showcasing Helix's leadership in ADC technology [2] - CEACAM6 was identified as a promising therapeutic target due to its high expression in various epithelial cancers, association with poor clinical outcomes, and limited presence in healthy tissues [3] - Data presented demonstrated the tumor-selective binding profile of Helix's proprietary anti-CEACAM6 VHH, supporting the development of next-generation ADCs that minimize off-target effects while delivering potent therapeutic payloads [3][4] Group 2: Company Pipeline and Innovations - Helix's lead candidate, Tumor Defense Breaker™ L-DOS47, is designed to enhance the sensitivity of CEACAM6-expressing tumors to therapy and has shown favorable safety and clinical activity in Phase I/II studies for non-small cell lung cancer (NSCLC) [6] - The company is also advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a first-in-class oral gemcitabine prodrug with bioavailability comparable to intravenous administration [6]